Lung involvement in connective tissue diseases: A comprehensive review and a focus on rheumatoid arthritis

Autoimmunity Reviews

Volumn 12, Issue 11, 2013, Pages 1076-1084

  Marigliano, Benedetta ^a   Soriano, Alessandra ^a   Margiotta, Domenico ^a   Vadacca, Marta ^a   Afeltra, Antonella ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Connective tissue diseases (CTDs); Idiopathic pulmonary fibrosis (IPF); Interstitial lung disease (ILD); Rheumatoid arthritis (RA); Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE;

CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; EMPHYSEMA; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG COMPLICATION; LUNG FIBROSIS; LUNG INJURY; LUNG TRANSPLANTATION; MEDICAL SOCIETY; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS;

CONNECTIVE TISSUE DISEASES (CTDS); IDIOPATHIC PULMONARY FIBROSIS (IPF); INTERSTITIAL LUNG DISEASE (ILD); RHEUMATOID ARTHRITIS (RA); TREATMENT;

ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; PULMONARY FIBROSIS;

EID: 84881552085     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.05.001     Document Type: Review

References (137)

1. Turesson C. Extra-articular rheumatoid arthritis. Cur Opin Rheumatol 2013, 25(5):360-366.
2. Ward J., McDonald C. Interstitial lung disease. An approach to diagnosis and management. Aust Fam Physician 2010, 39(3):106-110.
3. De Lauretis A., Veeraraghavan S., Renzoni E. Connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?. Chron Respir Dis 2011, 8(1):53-82.
4. Afeltra A., Zennaro D., Garzia P., Vadacca M., Ruggiero A., Dardes N., et al. Prevalence of interstitial lung involvement in patients with connective tissue diseases assessed with high-resolution computed tomography. Scand J Rheumatol 2006, 35(5):388-394.
5. Ingegnoli F., Lubatti C., Ingegnoli A., Boracchi P., Zeni S., Meroni P.L. Interstitial lung disease outcomes by high-resolution computed tomograpthy (HRCT) in anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 2012, 11(5):335-340.
6. Bussone G., Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011, 10(5):248-255.
7. Winklehner A., Berger N., Maurer B., Distler O., Alkadhi H., Frauenfelder T. Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 2012, 71(4):549-552.
8. Ascherman D.P. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep 2010, 12(5):363-369.
9. Behr J., Vogelmeier C., Beinert T., Meurer M., Krombach F., König G., et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996, 154(2 Pt 1):400-406.
10. Goh N.S.L., Veeraraghavan S., Desai S.R., Cramer D., Hansell D.M., Denton C.P., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 2007, 56(6):2005-2012.
11. Demedts M., Costabel U. ATS/ERS International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J 2002, 19(5):794-796.
12. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002, 165(2):277-304.
13. Hunninghake G.W., Zimmerman M.B., Schwartz D.A., King T.E., Lynch J., Hegele R., et al. Utility of lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 164(2):193-196.
14. Kim Dong Soon, Harold R.C., Talmadge E.K. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006, 3(4):285-292.
15. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157(pt 1):1301-1315.
16. Raghu G., Mageto Y.N., Lockhart D., Schmidt R.A., Wood D.E., Godwin J.D. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: a prospective study. Chest 1999, 116(5):1168-1174.
17. Coultas D.B., Zumwalt R.E., Black W.C., Sobonya R.E. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med 1994, 150(4):967-972.
18. Morgenthau A.S., Padilla M.L. Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med 2009, 76(1):2-23.
19. Hanak V., Ryu J.H., de Carvalho E., Limper A.H., Hartman T.E., Decker P.A., et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med 2008, 102(6):852-856.
20. Davies H.R., Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002, 1(3):211-224.
21. King T.E., Albera C., Bradford W.Z., Costabel U., Hormel P., Lancaster L., et al. Effect of interpheron gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomized, placebo-controlled trial. Lancet 2009, 374(9685):222-228.
22. Selman M., King T.E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001, 134(2):136-151.
23. Selman M., Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003, 29(3 Suppl.):S93-S97.
24. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., et al. IFIGENIA study group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353(21):2229-2242.
25. Bradley B., Branley H.M., Egan J.J., Greaves M.S., Hansell D.M., Harrison N.K., et al. Interstitial lung disease guidelines: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008, 63(Suppl. 5):v1-v58.
26. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
27. McGrath E.E., Millar A.B. Hot off the breath: triple therapy for idiopathic pulmonary fibrosis-hear the PANTHER roar. Thorax 2012, 67(2):97-98.
28. Travis W.D., Hunninghake G., Talmadge E.K., Lynch D.A., Colby T.V., Galvin J.R., et al. Idiopathic nonspecific interstitial pneumonia. Report of an American Thoracic Society project. Am J Respir Crit Care Med 2008, 177(12):1338-1347.
29. Kinder B.W., Collard H.R., Koth L., Daikh D.I., Wolters P.J., Elicker B., et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med 2007, 176(7):691-697.
30. Lee Hyun-Kyung, Kim Dong Soon, Yoo Bin, Seo J.B., Rho J.Y., Colby T.V., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005, 127(6):2019-2027.
31. Hartman T.E., Swensen S.J., Hansell D.M., Colby T.V., Myers J.L., Tazelaar H.D., et al. Nonspecific interstitial pneumonia: variable appearance at high-resolution chest CT. Radiology 2000, 217(3):701-705.
32. Hunninghake G.W., Lynch D.A., Galvin J.R., Gross B.H., Müller N., Schwartz D.A., et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003, 124(4):1215-1223.
33. MacDonald S.L., Rubens M.B., Hansell D.M., Copley S.J., Desai S.R., du Bois R.M., et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001, 221(3):600-605.
34. Flaherty K.R., Thwaite E.L., Kazerooni E.A., Gross B.H., Toews G.B., Colby T.V., et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003, 58(2):143-148.
35. Nicholson A.G., Colby T.V., du Bois R.M., Hansell D.M., Wells A.U. The prognostic significance of the histopathologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000, 162(6):2213-2217.
36. Poletti V., Romagnoli M., Piciucchi S., Chilosi M. Current status of idiopathic nonspecific interstitial pneumonia. Semin Respir Crit Care Med 2012, 33(5):440-449.
37. Mosca M., Tani C., Neri C., Baldini C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006, 6(1):1-4.
38. Kinder B.W., Shariat C., Collard H.R., Koth L.L., Wolters P.J., Golden J.A., et al. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function. Lung 2010, 188(2):143-149.
39. Bodolay E., Szekanecz Z., Dévényi K., Galuska L., Csípo I., Vègh J., et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford) 2005, 44(5):656-661.
40. Prakash U.B. Respiratory complications in mixed connective tissue disease. Clin Chest Med 1998, 19(4):733-746.
41. Sullivan W.D., Hurst D.J., Harmon C.E., Esther J.H., Agia G.A., Maltby J.D., et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984, 63(2):92-107.
42. Gunnarsson R., Aaløkken T.M., Molberg Ø., Lund M.B., Mynarek G.K., Lexberg A.S., et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012, 71(12):1966-1972.
43. Tanaka N., Kim J.S., Newell J.D., Brown K.K., Cool C.D., Meehan R., et al. Rheumatoid arthritis-related lung diseases: CT findings. Radiology 2004, 232(1):81-91.
44. Flaherty K.R., Colby T.V., Travis W.D., Toews G.B., Mumford J., Murray S., et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 2003, 167(10):1410-1415.
45. Song J.W., Do K., Kim M.Y., Jang S.J., Colby T.V., Kim D.S. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest 2009, 136(1):23-30.
46. Thorbecke G.J., Amin A.R., Tsiagbe V.K. Biology of germinal centers in lymphoid tissue. FASEB J 1994, 8(11):832-840.
47. Wen L., Pao W., Wong F.S., Peng Q., Craft J., Zheng B., et al. Germinal center formation, immunoglobulin class switching, and autoantibody production driven by non alpha/beta T cells. J Exp Med 1996, 183(5):2271-2282.
48. Luzina I.G., Atamas S.P., Storrer C.E., daSilva L.C., Kelsoe G., Papadimitriou J.C., et al. Spontaneous formation of germinal centers in autoimmune mice. J Leukoc Biol 2001, 70(4):578-584.
49. Nakamura Y., Chida K., Suda T., Hayakawa H., Iwata M., Imokawa S., et al. Nonspecific interstitial pneumonia in collagen vascular disease: comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003, 20(3):235-241.
50. Park J.H., Kim D.S., Park I.N., Jang S.J., Kitaichi M., Nicholson A.G., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175(7):705-711.
51. Lazor R., Vandevenne A., Pelletier A., Leclerc P., Court-Fortune I., Cordier J.F. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. Am J Respir Crit Care Med 2000, 162(2 Pt 1):571-577.
52. Watanabe K., Senju S., Wen F.Q., Shirakusa T., Maeda F., Yoshida M. Factors related to the relapse of bronchiolitis obliterans organizing pneumonia. Chest 1998, 114(6):1599-1606.
53. Imasaki T., Yoshii A., Tanaka S., Ogura T., Ishikawa A., Takahashi T. Polymyositis and Sjogren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Intern Med 1996, 35(3):231-235.
54. Kim E.A., Lee K.S., Johkoh T., Kim T.S., Suh G.Y., Kwon O.J., et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics 2002, 22 Spec No:S151-S165.
55. Douglas W.W., Tazelaar H.D., Hartman T.E., Hartman R.P., Decker P.A., Schroeder D.R., et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164(7):1182-1185.
56. Taylor J.G., Bolster M.B. Bronchiolitis obliterans with organizing pneumonia associated with scleroderma and scleroderma spectrum diseases. J Clin Rheumatol 2003, 9(4):239-245.
57. Stey C., Truninger K., Marti D., Vogt P., Medici T.C. Bronchiolitis obliterans organizing pneumonia associated with polymyalgia rheumatic. Eur Respir J 1999, 13(4):926-929.
58. Kaushik P., Cooper E.S., Banda V.R., Vatsavai S.R., Kaushik R. Bronchiolitis obliterans with organizing pneumonia in rheumatoid arthritis - a fatal case and short review of literature. Rheumatol Int 2005, 25(5):391-393.
59. Yoo J.W., Song J.W., Jang S.J., Lee C.K., Kim M.Y., Lee H.K., et al. Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia. Rheumatology (Oxford) 2011, 50(5):932-938.
60. Cottin V., Nunes H., Mouthon L., Gamondes D., Lazor R., Hachulla E., et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011, 63(1):295-304.
61. Munson J.C. Combined pulmonary fibrosis and emphysema: a high-pressure situation. Eur Respir J 2010, 35(1):9-11.
62. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009, 34(6):1219-1263.
63. Mejia M., Carrillo G., Rojas-Serrano J., Estrada A., Suárez T., Alonso D., et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009, 136(1):10-15.
64. Cottin V., Le Pavec J., Prevot G., Mal H., Humbert M., Simonneau G., et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010, 35(1):105-111.
65. Vij R., Strek M.E. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest 2013, 143(3):814-824.
66. Nannini C., Ryu J.H., Matteson E.L. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20(3):340-346.
67. Zou Y.Q., Li Y.S., Ding X.N., Ying Z.H. The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China. Rheumatol Int 2012, 32(3):669-673.
68. Antoniou K.M., Margaritopoulos G., Economidou F., Siafakas N.M. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009, 33(4):882-896.
69. Carmona L., Gonzalez-Alvaro I., Balsa A., Angel Belmonte M., Tena X., Sanmartí R. Rheumatoid arthritis in Spain. Occurrence of extrarticular manifestations and estimates of disease severity. Ann Rheum Dis 2003, 62(9):897-900.
70. Bilgici A., Ulusoy H., Kuru O., Celenk C., Unsal M., Danaci M. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int 2005, 25(6):429-435.
71. Dawson J.K., Fewins H.E., Desmond J., Lynch M.P., Graham D.R. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax 2001, 56(8):622-627.
72. Demir R., Bodur H., Tokoglu F., Olcay I., Uçan H., Borman P. High resolution computed tomography of the lungs in patients with rheumatoid arthritis. Rheumatol Int 1999, 19(1-2):19-22.
73. Gabbay E., Tarala R., Will R., Carroll G., Adler B., Cameron D., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997, 156(2 Pt 1):528-535.
74. Gochuico B.R., Avila N.A., Chow C.K., Novero L.J., Wu H.P., Ren P., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168(2):159-166.
75. Hassan W.U., Keaney N.P., Holland C.D., Kelly C.A. High resolution computed tomography of the lung in lifelong non-smoking patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54(4):308-310.
76. Mori S., Cho I., Koga Y., Sugimoto M. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. J Rheumatol 2008, 35(8):1513-1521.
77. Eunice J.K., Harold R.C., Talmadge E.K. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. Chest 2009, 136(5):1397-1405.
78. Lynch D.A. Lung disease related to collagen vascular disease. J Thorac Imaging 2009, 24(4):299-309.
79. Dawson J.K., Goodson N.G., Graham D.R., Lynch M.P. Raised pulmonary artery pressures measured with Doppler echocardiography in rheumatoid arthritis patients. Rheumatology (Oxford) 2000, 39(12):1320-1325.
80. Sihvonen S., Korpela M., Laippala P., Mustonen J., Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004, 33(4):221-227.
81. Rajasekaran A., Shovlin D., Saravanan V., Lord P., Kelly C. Interstitial lung disease in patients with rheumatoid arthritis: comparison with cryptogenic fibrosing alveolitis over 5years. J Rheumatol 2006, 33(7):1250-1253.
82. Hamilton J., Kelly C.A. What kills patients with rheumatoid arthritis?. Rheumatology (Oxford) 2007, 46(2):183-184.
83. Bongartz T., Nannini C., Medina-Velasquez Y.F., Achenbach S.J., Crowson C.S., Ryu J.H., et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population based study. Arthritis Rheum 2010, 62(6):1583-1591.
84. Dawson J.K., Fewins H.E., Desmond J., Lynch M.P., Graham D.R. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Ann Rheum Dis 2002, 61(6):517-521.
85. Kim Dong Soon Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 2006, 12(5):346-353.
86. Grutters J.C., du Bois R.M. Genetics of fibrosing lung disease. Eur Respir J 2005, 25(5):915-927.
87. Sugiyama Y., Ohno S., Kano S., Maeda H., Kitamura S. Diffuse panbronchiolitis and rheumatoid arthritis a possible correlation with HLA-B54. Intern Med 1994, 33(10):612-614.
88. Charles P.J., Sweatman M.C., Markwick J.R., Maini R.N. HLA-B40 a marker for susceptibility to lung disease in rheumatoid arthritis. Dis Markers 1991, 9(2):97-101.
89. Clarkson R., Bate A.S., Grennan D.M., Chattopadhyay C., Sanders P., Davis M., et al. DQw7 and C4B null allele in rheumatoid arthritis and felty's syndrome. Ann Rheum Dis 1990, 49(12):976-979.
90. Michalski J.P., McCombs C.C., Scopelitis E., Biundo J.J., Medsger T.A. Alpha 1-antitrypsin phenotypes in pulmonary disease associated with rheumatoid arthritis and systemic sclerosis. Arthritis Rheum 1986, 29(5):586-591.
91. Saag K.G., Cerhan J.R., Kolluri S., Ohashi K., Hunninghake G.W., Schwartz D.A. Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 1997, 56(8):463-469.
92. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(1):38-46.
93. Makrygiannakis D., Hermansson M., Ulfgren A.K., Nicholas A.P., Zendman A.J., Eklund A., et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis 2008, 67(10):1488-1492.
94. Manfredsdottir V.F., Vikingsdottir T., Jonsson T., Geirsson A.J., Kjartansson O., Heimisdottir M., et al. The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2006, 45(6):734-740.
95. Masdottir B., Jonsson T., Manfredsdottir V.F., Víkingsson A., Brekkan A., Valdimarsson H. Smoking, rheumatoid factor isotypes and severity of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39(11):1202-1205.
96. Nielen M.M.J., Van Schaardenburg D., Reesink H.W., van de Stadt R.J., van der Horst-Bruinsma I.E., de Koning M.H., et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50(2):380-386.
97. Oliver J.E., Silman A.J. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006, 35(3):169-174.
98. Gizinski A.M., Mascolo M., Loucks J.L., Kervitsky A., Meehan R.T., Brown K.K., et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular rheumatoid arthritis. Clin Rheumatol 2009, 28(5):611-613.
99. Fischer A., Solomon J.J., du Bois R.M., Deane K.D., Olson A.L., Fernandez-Perez E.R., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012, 106(7):1040-1047.
100. Kelly C., Saravanan V. Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease. Expert Opin Pharmacother 2008, 9(18):3221-3230.
101. Baugmnan R.P., Lower E.E. Use of intermittent intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992, 102(4):1090-1094.
102. Dayton C.S., Schwartz D.A., Helmers R.A., Pueringer R.J., Gilbert S.R., Merchant R.K., et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies. Chest 1993, 103(1):69-73.
103. Vassallo R., Thomas C.F. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol 2004, 16(3):186-191.
104. Mohr M., Jacobi A.M. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 2011, 40(5):400-401.
105. Lambotte O., Kotb R., Maigne G., Blanc F.X., Goujard C., Delfraissy J.F. Efficacy of rituximab in refractory polymyositis. J Rheumatol 2005, 32(7):1369-1370.
106. Kaushik V.V., Reddy H.V., Bucknall R.C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006, 65(8):1116-1117.
107. Sabnani I., Zucker M.J., Rosenstein E.D., Baran D.A., Arroyo L.H., Tsang P., et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford) 2009, 48(1):49-52.
108. Nishimoto N., Kishimoto T. Interleukin-6 from bench to bedside. Nat Clin Pract Rheumatol 2006, 2(11):619-626.
109. Madhok R., Crilly A., Watson J., Capell H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlation with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993, 52(3):232-234.
110. De Lauretis A., Sestini P., Pantelidis P., Hoyles R., Hansell D.M., Goh N.S., et al. Serum interleukin 6 is predictive of early funcional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013, 40(4):435-446.
111. Charman S.C., Sharples L.D., McNeil K.D., Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002, 21(2):226-232.
112. De Meester J., Smits J.M., Persijn G.G., Haverich A. Listing for lung transplantation: life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001, 20(5):518-524.
113. Mason D.P., Brizzio M.E., Alster J.M., McNeill A.M., Murthy S.C., Budev M.M., et al. Lung transplantation for idiopathic pulmonary fibrosis. Ann Thorac Surg 2007, 84(4):1121-1128.
114. Meyer D.M., Edwards L.B., Torres F., Jessen M.E., Novick R.J. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005, 79(3):950-957.
115. Lederer D.J., Arcasoy S.M., Wilt J.S., D'Ovidio F., Sonett J.R., Kawut S.M. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(6):659-664.
116. Trulock E.P. Lung transplantation. Am J Respir Crit Care Med 1997, 155(3):789-818.
117. Todd J.L., Palmer S.M. Bronchiolitis obliterans syndrome. The final frontier for lung transplantation. Chest 2011, 140(2):502-508.
118. Medoff B.D., Seung E., Wain J.C., Means T.K., Campanella G.S., Islam S.A., et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med 2005, 202(1):97-110.
119. Verleden G.M., Verleden S.E., Vos R., De Vleeschauwer S.I., Dupont L.J., Van Raemdonck D.E., et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int 2011, 24(7):651-656.
120. Simons S.O., Reijers M.H. Montelukast for bronchiolitis obliterans syndrome after lung transplantation. Chest 2012, 141(1):275-276.
121. Remy-Jardin M., Remy J., Cortet B., Mauri F., Delcambre B. Lung changes in rheumatoid arthritis CT findings. Radiology 1994, 193(2):375-382.
122. Casals-Ramos M., Perez-Alvarez R., Perez-de-lis M., Xaubet A., Bosch X., BIOGEAS Study Group Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases. Am J Med 2011, 124(5):386-394.
123. Saag K.G., Teng G.G., Patkar N.M., Anuntiyo J., Finney C., Curtis J.R., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59(6):762-784.
124. Saravanan V., Kelly C.A. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 2004, 43(2):143-147.
125. Barrera P., Laan R.F., van Riel P.L., Dekhuijzen P.N., Boerbooms A.M., van de Putte L.B. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994, 53(7):434-439.
126. Kamata Y., Nara H., Kamimura T., Haneda K., Iwamoto M., Masuyama J., et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004, 43(12):1201-1204.
127. Herrinton L.J., Harrold L.R., Liu L., Raebel M.A., Taharka A., Winthrop K.L., et al. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf 2013, 22(4):394-402.
128. Thavarajah K., Wu P., Rhew E.J., Yeldandi A.K., Kamp D.W. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009, 103(5):661-669.
129. Hagiwara K., Sato T., Takagi-Kobayashi S., Hasegawa S., Shigihara N., Akiyama O. Acute exacerbation of pre-existing interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007, 34(5):1151-1154.
130. Yousem S.A., Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. Mod Pathol 2005, 18(5):651-655.
131. Vavricka S.R., Wettstein T., Speich R., Gaspert A., Bachli E.B. Pulmonary granulomas after tumor necrosis factor alpha antagonist therapy. Thorax 2003, 58(3):278-279.
132. Ostor A.J., Crisp A.J., Somerville M.F., Scott D.G. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ 2004, 329(7477):1266.
133. Horai Y., Miyamura T., Shimada K., Takahama S., Minami R., Yamamoto M., et al. Etanercept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease. J Clin Pharm Ther 2012, 37(1):117-121.
134. Cain H.C., Noble P.W., Matthay R.A. Pulmonary manifestations of Sjogren's syndrome. Clin Chest Med 1998, 19(4):687-699.
135. Turner-Strokes L., Turner-Warwick M. Intrathoracic manifestations of SLE. Clin Rheum Dis 1982, 8(1):229-242.
136. Hainsworth J.D. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis. Arthritis Res Ther 2003, 5(Suppl. 4):S12-S16.
137. Sathi N., Urwin T., Desmond S., Dawson J.K. Patients with limited rheumatoid arthritis-related interstitial lung disease have a better prognosis than those with extensive disease. Rheumatology (Oxford) 2011, 50(3):620.